Intraocular T-cell Lymphoma: Medical Presentation, Prognosis, Remedy, and Final result.
Ocul Immunol Inflamm. 2017 Oct;25(5):639-648
Authors: Chaput F, Amer R, Baglivo E, Touitou V, Kozyreff A, Bron D, Bodaghi B, LeHoang P, Bergstrom C, Grossniklaus HE, Chan CC, Pe’er J, Caspers LE
PURPOSE: To report on the medical knowledge of seven sufferers with T-cell intraocular lymphoma (IOL).
METHODS: Retrospective case sequence.
RESULTS: Seven immunocompetent sufferers, 12 eyes, 6 ladies, with T-cell-IOL had been included from 5 nations. Imply age was 53.5 years (vary: 25-82). 4 sufferers had systemic-ocular lymphoma, two had CNS-ocular lymphoma, and one had systemic-CNS- ocular lymphoma. Vitritis was probably the most frequent medical signal, adopted by anterior uveitis and serous retinal detachment. Cytopathologic examination was carried out on all ocular specimens (vitreous in six and iris mass biopsy in a single affected person). Adjunctive diagnostic procedures included immunohistochemistry, molecular checks, and cytokine profiling of vitreous samples. Remedy modalities included systemic chemotherapy (5 sufferers), intravitreal methotrexate (three sufferers), globe radiotherapy, and intrathecal chemotherapy. Imply survival from analysis was 21.7 months (vary: 2-69). Two sufferers are nonetheless alive.
CONCLUSIONS: T-cell IOL has variable medical manifestations and prognosis. Systemic involvement, SRD, and vitreoretinal involvement had been incessantly noticed.
PMID: 27002464 [PubMed – indexed for MEDLINE]